Reimbursement and HTA hurdles frustrate new EU member states
This article was originally published in Clinica
Now that the ten new EU member states have been part of the European Community for just over a year, enjoying the benefits of free trade in medical devices and diagnostics that have come with regulatory alignment, they are finding reimbursement issues the new barriers to trade.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.